The MarketWatch News Department was not involved in the creation of this content. Nation's largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates ...
A Settlement, Not a Sigh of Relief: What the FTC’s Express Scripts Deal Signals for Enforcement Risk
The FTC’s newly announced settlement with Express Scripts marks a pivotal moment in the government’s campaign against pharmacy benefit manager pricing practices—and it should be read as more than a ...
Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers. Today, Bernstein Litowitz Berger & Grossmann LLP (BLB&G) ...
A Settlement, Not a Sigh of Relief: What the FTC’s Express Scripts Deal Signals for Enforcement Risk
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...
The Federal Trade Commission has announced what it called a "landmark settlement" with Express Scripts over insulin pricing. The settlement resolves a lawsuit alleging that Express Scripts' conduct ...
The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin. “Caremark, [Express Scripts], and Optum—as medication ...
The Federal Trade Commission has reached a landmark settlement with Express Scripts, one of the nation’s largest pharmacy benefit managers, requiring sweeping changes aimed at lowering insulin costs ...
The Federal Trade Commission said it has reached a settlement with Express Scripts, resolving an earlier lawsuit that alleged the pharmacy benefit manager artificially inflated insulin drug prices.
Cigna Corp's Express Scripts has settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at ...
The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices. By Rebecca Robbins and Reed Abelson The reporters have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results